This phase II trial studies how well retroperitoneal lymph node dissection (RPLND) works in treating patients with stage I-IIa testicular seminoma. The retroperitoneum is the space in the body behind the intestines that is typically the first place that seminoma spreads. RPLND is a surgery that removes lymph nodes in this area to treat testicular seminoma and may experience fewer long-term toxicities, such as a second cancer, cardiovascular disease, metabolic syndrome (pre-diabetes), or lung disease.
PRIMARY OBJECTIVES: I. Assess the recurrence free survival (RFS) at 2 years after RPLND when RPLND is used as a first line treatment for patients with testicular seminoma and low volume (=\< 2cm) retroperitoneal disease. SECONDARY OBJECTIVES: I. Estimate the percent of patients, after treatment with RPLND, who can avoid external beam radiotherapy (XRT) or systemic chemotherapy (CTX) for seminoma. II. Assess the complications associated with primary RPLND for seminoma. OUTLINE: Patients undergo RPLND. After completion of study treatment, patients are followed up at 1 month, every 4 months for 1 year, every 6 months for 2 years, and then annually thereafter.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
TREATMENT
Masking
NONE
Enrollment
55
Correlative studies
Undergo RPLND
Loma Linda University Medical Center
Loma Linda, California, United States
USC / Norris Comprehensive Cancer Center
Los Angeles, California, United States
University of California, San Francisco
San Francisco, California, United States
Stanford University Hospitals & Clinics
Stanford, California, United States
University of Colorado Hospital - Aurora
Aurora, Colorado, United States
Emory University
Atlanta, Georgia, United States
University of Chicago Medical Center
Chicago, Illinois, United States
Indiana University
Indianapolis, Indiana, United States
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Baltimore, Maryland, United States
Mayo Clinic
Rochester, Minnesota, United States
...and 4 more locations
RFS
Associated 95% confidence intervals will be constructed. Actuarial RFS will be calculated by the Kaplan Meier method. The recurrence location (pelvic, retroperitoneal, distant) will be calculated as a percentage of total recurrences to describe the clinical pattern of disease after relapse.
Time frame: From RPLND to the time of recurrence or death, whichever comes first., assessed at 2 years after RPLND
Long-term RPLND complication rates
The rate of short and long term complications will be calculated.
Time frame: Up to 5 years
RFS
Associated 95% confidence intervals will be constructed. Actuarial RFS will be calculated by the Kaplan Meier method.
Time frame: From RPLND to the time of recurrence or death, whichever comes first., assessed at 5 years after RPLND
Short-term RPLND complication rates
The rate of short and long term complications will be calculated.
Time frame: Up to 12 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.